Targeting chelatable iron as a therapeutic modality in Parkinson''s disease. Devos, D; Moreau, C; Devedjian, J.; Kluza, J; Petrault, M; Laloux, C; Jonneaux, A; Ryckewaert, G; Garçon, G; Rouaix, N; Duhamel, A; Jissendi, P; Dujardin, K; Auger, F; Ravasi, L; Hopes, L; Grolez, G; Firdaus, W; Sablonnière, B; Strubi-Vuillaume, I; Zahr, N; Destée, A; Corvol, J.; Pöltl, D; Leist, M; Rose, C; Defebvre, L; Marchetti, P; Cabantchik, Z.; and Bordet, R Antioxid Redox Signal, 21:195–210, 2014.
doi  bibtex   
@article{devos_targeting_2014,
	title = {Targeting chelatable iron as a therapeutic modality in {Parkinson}''s disease.},
	volume = {21},
	issn = {1557-7716},
	doi = {10.1089/ars.2013.5593},
	language = {English},
	journal = {Antioxid Redox Signal},
	author = {Devos, D and Moreau, C and Devedjian, JC and Kluza, J and Petrault, M and Laloux, C and Jonneaux, A and Ryckewaert, G and Garçon, G and Rouaix, N and Duhamel, A and Jissendi, P and Dujardin, K and Auger, F and Ravasi, L and Hopes, L and Grolez, G and Firdaus, W and Sablonnière, B and Strubi-Vuillaume, I and Zahr, N and Destée, A and Corvol, JC and Pöltl, D and Leist, M and Rose, C and Defebvre, L and Marchetti, P and Cabantchik, ZI and Bordet, R},
	year = {2014},
	pages = {195--210}
}
Downloads: 0